Press releases
- ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024
- ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
- IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024
- ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
- IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
- ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
- BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
- IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
More ▼
Key statistics
On Friday, Immunoprecise Antibodies Ltd (TQB:FRA) closed at 0.69, 0.73% above its 52-week low of 0.685, set on Jul 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.69 |
---|---|
High | 0.69 |
Low | 0.69 |
Bid | 0.69 |
Offer | 0.85 |
Previous close | 0.725 |
Average volume | 888.20 |
---|---|
Shares outstanding | 26.32m |
Free float | 22.74m |
P/E (TTM) | -- |
Market cap | 22.63m USD |
EPS (TTM) | -0.4092 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 07:12 BST.
More ▼